全文获取类型
收费全文 | 6576篇 |
免费 | 289篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 99篇 |
妇产科学 | 74篇 |
基础医学 | 756篇 |
口腔科学 | 94篇 |
临床医学 | 393篇 |
内科学 | 1636篇 |
皮肤病学 | 126篇 |
神经病学 | 509篇 |
特种医学 | 419篇 |
外科学 | 1286篇 |
综合类 | 33篇 |
一般理论 | 1篇 |
预防医学 | 205篇 |
眼科学 | 61篇 |
药学 | 412篇 |
中国医学 | 14篇 |
肿瘤学 | 758篇 |
出版年
2023年 | 35篇 |
2022年 | 103篇 |
2021年 | 165篇 |
2020年 | 95篇 |
2019年 | 104篇 |
2018年 | 139篇 |
2017年 | 136篇 |
2016年 | 151篇 |
2015年 | 142篇 |
2014年 | 182篇 |
2013年 | 234篇 |
2012年 | 375篇 |
2011年 | 438篇 |
2010年 | 272篇 |
2009年 | 216篇 |
2008年 | 395篇 |
2007年 | 396篇 |
2006年 | 433篇 |
2005年 | 417篇 |
2004年 | 388篇 |
2003年 | 342篇 |
2002年 | 340篇 |
2001年 | 88篇 |
2000年 | 91篇 |
1999年 | 105篇 |
1998年 | 83篇 |
1997年 | 59篇 |
1996年 | 64篇 |
1995年 | 59篇 |
1994年 | 58篇 |
1993年 | 60篇 |
1992年 | 83篇 |
1991年 | 64篇 |
1990年 | 47篇 |
1989年 | 63篇 |
1988年 | 58篇 |
1987年 | 58篇 |
1986年 | 53篇 |
1985年 | 58篇 |
1984年 | 42篇 |
1983年 | 27篇 |
1982年 | 22篇 |
1981年 | 15篇 |
1980年 | 14篇 |
1979年 | 30篇 |
1978年 | 23篇 |
1977年 | 16篇 |
1975年 | 9篇 |
1974年 | 11篇 |
1972年 | 9篇 |
排序方式: 共有6916条查询结果,搜索用时 15 毫秒
81.
Kan Yonemori Yasutoshi Kuboki Kosei Hasegawa Takashi Iwata Hidenori Kato Kazuhiro Takehara Yasuyuki Hirashima Hisamori Kato Chaitali Passey Jeppe Klint Buchbjerg Jeffrey R. Harris Camilla
Mondrup Andreassen Leonardo Nicacio Ibrahima Soumaoro Keiichi Fujiwara 《Cancer science》2022,113(8):2788
New treatments, particularly second‐line options, are needed to improve outcomes for patients with recurrent/metastatic cervical cancer (r/mCC). Tisotumab vedotin (TV) is an antibody–drug conjugate directed to tissue factor, a transmembrane protein commonly expressed in cancer cells, to deliver cytotoxic monomethyl auristatin E. This single‐arm, open‐label phase 1/2 trial evaluated the consistency of safety and efficacy outcomes of TV in Japanese patients with r/mCC to bridge the current findings with those reported in previous trials in non‐Japanese patients in the United States and Europe. In part 1 (dose escalation; N = 6), patients with advanced solid tumors received TV 1.5 or 2.0 mg/kg once every 3 weeks to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 (dose expansion; N = 17) evaluated the RP2D in r/mCC patients with 1–2 prior lines of therapy. In part 1, no dose‐limiting toxicities were observed, the MTD was not reached, and TV 2.0 mg/kg was established as the RP2D. In part 2, the most common treatment‐emergent adverse events were anemia (58.8%), nausea (58.8%), alopecia (47.1%), epistaxis (47.1%), and diarrhea (35.3%); adverse events of special interest were bleeding (76.5%), ocular events (35.3%), and peripheral neuropathy (17.6%), and were mostly grade 1/2. In part 2, confirmed objective response rate was 29.4%, median duration of response was 7.1 months, and median time to response was 1.2 months. In Japanese patients with r/mCC, TV demonstrated a manageable and tolerable safety, pharmacokinetics, and efficacy profile consistent with that observed in non‐Japanese patients. 相似文献
82.
Isao Suzaki Yurika Kimura Akihiko Tanaka Kojiro Hirano Atsushi Ishibashi Tomomi Mizuyoshi Izumi Ando Tatsuya Kitajima So Watanabe Yasuyuki Hinohira Hitome Kobayashi 《Auris, nasus, larynx》2019,46(1):141-146
Eosinophilic otitis media (EOM), which is characterized by the accumulation of eosinophils in middle ear effusion and the middle ear mucosa, is a refractory type of otitis media that is often associated with asthma. Although an early diagnosis and appropriate treatment are necessary to prevent the progression of hearing loss in patients with EOM, there are currently no well-established treatments for this condition. We treated a 60-year-old male patient with asthma and EOM. The patient’s asthma was poorly controlled, despite the use of high-dose inhaled corticosteroids, long-acting beta-agonist treatment, and the regular use of systemic corticosteroids. Mepolizumab, an anti-IL-5 monoclonal antibody, was started to treat the patient’s refractory asthma. At 4 months after the initiation of mepolizumab treatment, the patient’s asthma, hearing, and middle ear effusion improved. The present case suggests that mepolizumab therapy can control EOM and asthma. 相似文献
83.
84.
Tomofumi Fujino Akihito Yokosuka Hideaki Higurashi Rina Yokokawa Ryo Sakurai Wataru Harashima Yuichi Miki Yasuyuki Fujiwara Yoshihiro Mimaki Makio Hayakawa 《Journal of natural medicines》2017,71(1):36-43
Here, we show that AU-1, spirostanol saponin isolated from Agavaceae plants, causes a transient increase in cyclin-dependent kinase inhibitor (CDKI) p21/Cip1 through the upregulation of miRNAs, miR-34 and miR-21. AU-1 stimulated p21/Cip1 expression without exerting cytotoxicity against different types of carcinoma cell lines. In renal adenocarcinoma ACHN cells, AU-1 transiently elevated the expression level of p21/Cip1 protein without marked increases in p21/Cip1 mRNA levels. Rapid and transient increases in miR-34 and miR-21, both of which are known to upregulate p21/Cip1, were observed in AU-1-treated cells. Inhibitor for miR-34 and for miR-21 significantly blocked the AU-1-caused increase in p21/Cip1, indicating that elevation of p21/Cip1 protein by AU-1 is dependent on these microRNAs. We further clarified that NAD-dependent deacetylase SIRT1, a direct target of miR-34, is decreased by the treatment with AU-1. Furthermore, we found that SIRT1-knockdown increases p21/Cip1 protein levels in an miR-21-dependent manner. On the other hand, ectopic expression of p21/Cip1 resulted in the lowered expression of miR-34 and miR-21, suggesting that reciprocal regulation exists between p21/Cip1 and these miRNAs. We propose that the following feedback network composed of miR-34/SIRT1/miR-21/p21 is triggered by the treatment with AU-1: in cells treated with AU-1, transient elevation of miR-34 leads to the downregulation of SIRT1, thereby miR-21 is freed from SIRT1-dependent suppression. Then, elevated miR-21 upregulates p21/Cip1 protein, followed by the suppression of miR-34 expression. 相似文献
85.
86.
Atsushi Masuyama Hitomi Kobayashi Yasuyuki Kobayashi Isamu Yokoe Yusuke Sugimura Keiichiro Maniwa Hiroshi Sato Tsuyoshi Ishida Yuki Hatanaka 《Modern rheumatology / the Japan Rheumatism Association》2013,23(2):379-385
We present a patient who had adult-onset Still’s disease (AOSD) complicated by thrombotic thrombocytopenic purpura (TTP) that resulted in retinal microangiopathy and rapidly fatal cerebral edema. The patient was a 37-year-old male who developed fever, eruption, arthritis and hepatic dysfunction, that, based on close examination, was diagnosed as AOSD. Despite treatment with corticosteroids, the patient developed acute visual field defect, neurological deterioration including convulsions and impaired consciousness, as well as acute renal failure that ultimately resulted in death. Pathological examination of autopsy specimens revealed multiple fibrin thrombi disseminated in small vessels of the brain and kidney, which was consistent with TTP, along with marked cerebral edema. Although TTP has rarely been reported in association with AOSD, awareness of the possible coexistence of these two diseases is important for diagnosis and treatment. 相似文献
87.
Yukiko Hasuike Naoto Kakita Makoto Aichi Satoko Masachika Mari Kantou Shoko Ikeda Takahashi Masayoshi Nanami Yasuyuki Nagasawa Takahiro Kuragano Takeshi Nakanishi 《Journal of vascular surgery》2019,69(1):174-180.e2
Objective
For patients with end-stage renal disease on hemodialysis, the durability of vascular access (VA) is still far from optimal, and access survival after intervention for access failure is an important aspect. Procoagulant status is a leading cause of access failure. Coagulation-fibrinolysis imbalance can occur in hemodialyzed patients, but the influence of the imbalance has not been fully elucidated.Methods
We prospectively examined coagulation-fibrinolysis balance to assess the risk of access failure after the intervention of revascularization in a cohort of 462 hemodialysis patients. Thrombin-antithrombin complex (TAT) and plasmin-α2-plasmin inhibitor complex (PIC) are markers for coagulation and fibrinolysis. Median follow-up was 243 days. The end point was clinical access failure: revascularization or access revision. The survival curve for VA patency was assessed using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards regression models that allowed adjustment for baseline differences in age, sex, dialysis vintage, diabetes mellitus, and various factors (quantity of blood flow, prothrombin time-international normalized ratio, fibrin degradation products, C-reactive protein, interleukin-6, tumor necrosis factor-α, and pentraxin-3) were used.Results
The 162 patients who reached an end point had smaller access flow volume and smaller percentage of arteriovenous fistula and higher TAT/PIC ratio. Kaplan-Meier analysis indicated that the patients with elevated TAT/PIC ratio showed poorer outcome (P < .001). On Cox regression modeling, elevated TAT/PIC was an independent risk factor for access failure (hazard ratio, 1.58; P = .03).Conclusions
Our results suggest that coagulation-fibrinolysis imbalance is a significant risk factor for access failure and may predict VA failure in hemodialyzed patients after access intervention. 相似文献88.
89.
90.
Akiko Danjo Kanako Yamaguchi Kazuma Fujimoto Toshihito Saitoh Masahiko Inamori Takashi Ando Tomohiko Shimatani Kyoichi Adachi Fukunori Kinjo Shiko Kuribayashi Shoji Mitsufuji Yasuhiro Fujiwara Shigeki Koyama Junichi Akiyama Atsushi Takagi Noriaki Manabe Hiroto Miwa Yasuyuki Shimoyama Motoyasu Kusano 《Journal of gastroenterology and hepatology》2009,24(4):633-638
Background and Aim: We compared endoscopic findings of the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG), a written questionnaire developed in Japan, to that for the questionnaire for the diagnosis of reflux esophagitis (QUEST) for the diagnosis of reflux esophagitis. Methods: We registered 475 patients with untreated symptoms of upper abdominal pain (male/female: 252/223, average age 52.4 ± 17.8 years). Subjects were assessed first with the FSSG and QUEST questionnaires, then by endoscopy, before allocation to a gastric ulcer (GU), duodenal ulcer (DU), gastroesophageal reflux disease (GERD) or functional dyspepsia (FD) group. Results: On the basis of the endoscopic findings the diagnoses for the 475 subjects were as follows: FD 52.2%, DU 7.6%, GU 7.8%, and GERD 32.4% (Grade M 10.1%, Grade A + B 20.2%, Grade C + D 2.3%). There was no difference between the FSSG and QUEST in sensitivity, specificity or accuracy for any condition. The FSSG score rose with increasing endoscopic severity of GERD, but there was no correlation between the QUEST score and endoscopic severity. The FSSG total score was inferior to QUEST in terms of distinguishing GERD from other conditions, but when only the questions relating to reflux symptoms were used, the FSSG was able to distinguish GERD from other conditions as well as QUEST. Conclusions: The FSSG score reflects the severity of the endoscopic findings of GERD. 相似文献